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Abstract
Background: We evaluated the cancer detection rate of prostate cancer using transperineal template-guided
saturation biopsy aimed at sampling one core for each milliliter of prostate volume for patients requiring repeated
prostate biopsies.
Methods: In total, 103 consecutive patients with repeated prostate biopsies were enrolled in this retrospective study.
The number of biopsy cores was defined by prostate volume. In principle, one biopsy core covered 1 mL of prostate
volume. We used a prostate brachytherapy template with a 5-mm grid and adopted a transperineal needle biopsy.
Results: The median age, prostate-specific antigen level, and prostate volume were 69 (range, 37–83) years, 9.2 (range,
1.9–107) ng/mL, and 34.7 (range, 18–76.7) mL, respectively. The median number of biopsy cores was 37 (range, 18–75
cores). Fifty-three patients (51.5%) were diagnosed with prostate cancer. The Gleason score was 6, 7, and 8–10 in 24.5,
64.2 and 11.3% patients, respectively. Forty-two patients (79.2%) were diagnosed with clinically significant PCa. Acute
urinary retention was detected in 2 patients (1.9%).
Conclusions: Transperineal template-guided saturation biopsy with one core per milliliter of prostate volume helped
achieve a high cancer detection rate and high significant cancer detection rate with acceptable biopsy-associated
adverse events.
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Background
Prostate-specific antigen (PSA) testing has been widely
used for prostate cancer (PCa) screening, and transrectal
ultrasound (TRUS)-guided biopsies have been widely per-
formed [1, 2]. However, even with contemporary use of
laterally directed extended TRUS-guided biopsies, the
false-negative rate remains high [3]. Patients with negative
diagnosis by TRUS-guided biopsy may need repeat biopsy
if the following findings are present: increased PSA levels;
abnormal findings on digital rectal examination (DRE),
TRUS, and MRI; and previous biopsy showing high-grade
prostatic intraepithelial neoplasia (HGPIN) and/or atypical
small acinar proliferation (ASAP). Cancer detection rates
with TRUS-guided repeat biopsy have been reported to
range from 10 to 21% [4–6]. These results indicate that
patients continue to be under persistent clinical suspicion
of PCa despite several repeated biopsies. To resolve this
problem, several investigators have reported the use of sat-
uration biopsy [7–12].
Prostate saturation biopsy was initially introduced by
Borborogle et al. [7]; it consisted at least 20 biopsy cores. Sat-
uration biopsy is performed via transrectal or transperineal
routes, with similarly high detection rates [8–13]. Recently,
the transperineal approach has been preferred because of
sampling accuracy, particularly for the anterior prostate
region [8–10]. Although the technique of transperineal
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saturation biopsy has varied among reports, the cancer detec-
tion rate has been reported to be between 40 and 60% in re-
peated biopsies [8–10, 14, 15]. Previous studies on saturation
repeat biopsy showed higher detection rates than those on
TRUS-guided repeat biopsy. However, the optimal number
of biopsy cores remains in dispute. Buskirk et al. [16] showed
that the number of needle incursions was the only prognostic
factor of acute urinary retention (AUR). The incidence of
AUR has been reported to be 10–39% [10, 17–19]. To pre-
vent AUR, Ekwueme et al. [9] demonstrated the efficacy of
transperineal saturation biopsy to avoid a needle incursion in
the periurethral region, and AUR rate was found to be only
5.2%. Furthermore, McNeal and Chen et al. reported that
PCa is rarely detected in the periurethral region [20, 21].
Under these circumstances, we conducted a study to
evaluate the efficacy and safety of transperineal template-
guided saturation biopsy (TTSB) aimed at sampling one
core for each milliliter of prostate volume for patients
who had undergone at least one negative TRUS-guided bi-
opsy and requiring repeated prostate biopsy for increased
PSA levels, abnormal findings on DRE, TRUS, and MRI,
previous biopsy showing HGPIN, or ASAP.
Methods
Patient selection
From January 2008 to July 2014, we offered transperineal
TTSB for patients considered to need prostate repeat
biopsy when the following clinical factors were present: in-
creased PSA levels; abnormal findings on DRE, TRUS, or
MRI; and a previous biopsy showing HGPIN and/or ASAP.
The number of previous TRUS-guided biopsies from TTSB
showed 1–5 negative biopsies (median: 1). A total of 103
consecutive patients who received TTSB repeated prostate
biopsy were enrolled in this study. Then we retrospectively
analyzed the data. The institutional review board of the
Nara Medical University approved this study.
Procedure of TTSB
All procedures were performed in the operating room.
TTSB was performed in the dorsal lithotomy position
under either general or spinal anesthesia; a 14-French ur-
ethral catheter was inserted before the procedure. Every
patient received premedication with a single dose of 1 g
cefazolin by intravenous infusion for preventing infection
caused by TTSB. DRE was performed, and a transrectal
probe (Toshiba Medical, Tochigi, Japan) attached to a
brachytherapy stepping unit (AccuSeed, Bedfordshire,
UK) was then inserted into the rectum. The low-echoic
area was estimated and prostate volume was calculated
using the following formula: length × width × height ×
0.5236 [22]. The number of biopsy cores was estimated
using the widest transverse section (Fig. 1). The interval
between biopsy cores in a row was uniformly 5 mm in
rows from right to left in the longitudinal view, except for
the area nearest to and around the urethra. At a point
where sufficient sample was not taken from the apex of
the bladder, an additional core was considered to take the
sample from a point near the bladder. The number of
additional cores taken was determined by the calculated
prostate volume, and the number of biopsy cores was
determined based on prostate volume. To achieve a
“saturation biopsy,” one biopsy core per milliliter of
prostate volume was required. The biopsy procedure was
performed using an 18-gauge, 25-cm-long biopsy gun
(Bard, Covington, GA, USA).
After TTSB, patients were monitored in the hospital
until the next day noon. The next morning, the urethral
catheter was removed. Patients were discharged once
they could void successfully.
PSA density (PSAD) was calculated by dividing PSA
by prostate volume. PSA velocity (PSAV) was defined as
absolute increase in PSA level per year following the ini-
tial biopsy until the second biopsy. For patients with
multiple PSA measurements prior to a saturation biopsy,
we used the most recent value before the saturation bi-
opsy date. Insignificant cancer was defined as a clinically
insignificant Gleason score of 3, maximum tumor length
of <4.5 mm, and total tumor length of <5.5 mm based
on the report by Epstein [23].
Statistical analysis
Statistical analysis was performed with SPSS for
Windows (version 20.0; IBM, Armonk, NY, USA).
Pearson’s correlation was calculated between pairs of
variables. A Mann-Whitney U test was used for continu-
ous variables and a chi-square test for categorical vari-
ables. Binary logistic regression analysis was used to
estimate the independent parameter of positive TTSB.
Fig. 1 Ultrasound image of the prostate showing the sites for
sampling (black dots). Triangle shows urethra. Circle shows sites
where sampling was avoided
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The cutoff value was determined as the point closest to
the upper left-hand corner in the receiver operating
characteristic curve. Univariate analysis was first applied
to isolate variables with a significant value of P < 0.05.
Variables predictive of PCa by univariate analysis were
included in multivariate analysis. A P value <0.05 was
considered statistically significant.
Results
The median age, median PSA level, and median prostate
volume were 69 (range, 37–83) years, 9.2 (range, 1.9–107)
ng/mL, and 34.7 (range, 18–76.7) mL, respectively. The
median number of previous TRUS biopsies sets was 1
(range, 1–5) and that of cores obtained by previous
TRUS-guided biopsies was 12 (range, 8–13). TTSB re-
sulted in a median of 37 cores (range, 18–75). Of the 103
patients, PCa was detected in 53 (51.5%). In 57 patients
with gray-zone PSA (4–10 ng/ml), PCa was detected in 25
(43.9%). Patient age with positive biopsy was significantly
higher than that with negative biopsy (P < 0.01), and PSAD
of positive biopsy patients was significantly higher than
that of negative biopsy patients (P = 0.02). Free PSA ratio
of positive was significantly lower than that of negative bi-
opsy patients (P = 0.04), abnormal findings on DRE were
found more in positive biopsy patients than in negative (P
= 0.03), and prostate volume of positive biopsy patients
was significantly smaller than that of negative biopsy pa-
tients (P < 0.01). MRI was performed for 14 patients be-
tween the previous TRUS-guided biopsy and TTSB, and 9
patients underwent saturation biopsy because of abnormal
findings on MRI. Six of nine patients (66.7%) were diag-
nosed with PCa on TTSB (Table 1)
Table 2 summarizes the number of positive cores and
Gleason biopsy score. The distribution of positive cores
was the most heavily weighted in those patients with 2–
5 positive cores (50.1%). Gleason score distribution
ranged from 6 to 9 with the vast majority 7 (64.2%).
Eleven patients (20.8%) were diagnosed with clinically
insignificant PCa.
In the cores taken from the posterior and anterior re-
gions of the prostate, PCa was detected in 33/53 (62.2%)
and 44/53 (83%) cases, respectively. The incidence of
PCa in the anterior region of the prostate was signifi-
cantly higher than that in the posterior (P = 0.01). GS ≥ 7
PCa was found in 24/53 (45.2%) and 31/53 (58.5%) cases
in the cores taken from the posterior and anterior re-
gions of the prostate, respectively. There was no signifi-
cant difference (P = 0.14 ) in the incidence of GS ≥ 7 PCa
between the posterior and anterior regions.
Age, free PSA ratio, PSA density, abnormal findings
on DRE, and prostate volume were the significant fac-
tors in univariate analysis. In multivariate analysis, pros-
tate volume was a negative predictor of positive PCa by
TTSB (≤34.1 vs. > 34.1 mL, P = 0.03) and age was a posi-
tive predictor of positive PCa by TTSB (≤70.3 vs. >
70.3 years, P < 0.01) (Table 3).
There was no case of urosepsis and urinary tract infec-
tion. Only 2 of 103 (1.9%) patients needed catheterization
after removal of the catheter. From one patient the ureth-
ral catheter could be removed after 6 days and from
Table 1 The clinical and pathological features of patients
Variables








Age, years 69 (37–83) 71 (48–79) 67 (37–83) <0.01†
No. of TRUS biopsies 1 (1–5) 1 (1–5) 1 (1–3) 0.48†
No. of cores obtained pre-TRUSBs 12 (8–13) 12 (8–13) 12 (8–12) 0.89†
PSA, ng/mL 9.2 (1.9–107) 10.7 (1.9–42.1) 8.8 (4.5–107) 0.33†
Free-PSA ratio, % 15.3 (1.3–67.1) 12.9 (4.3–25.7) 16.9 (1.3–67.1) 0.04†
PSA density, ng/mL/mL 0.26 (0.06–1.9) 0.33 (0.06–1.3) 0.23 (0.07–1.9) 0.02†
PSA velocity, ng/mL/year 1.12 (−29–129) 1.39 (−29–26) 0.75 (−8.8–129) 0.66
DRE, abnormal findings 17 (16.5) 13 (24.5) 4 (8.0) 0.03‡
TRUS, abnormal findings 21 (20.3) 14 (26.4) 7 (14.0) 0.13‡
MRI, abnormal findings (n = 14) 9/14 (64.2) 6/9 (66.7) 3/5 (60.0) 0.93‡
Prostate volume, mL 34.7 (18–76.7) 30.8 (18–65.1) 39.4 (20.1–76.7) <0.01†
HGPIN on previous biopsy 13 (12.6) 7 (13.2) 6 (12.0) 0.88‡
ASAP on previous biopsy 10 (9.7) 8 (15.1) 2 (4.0) 0.06‡
No of cores obtained by TTSB 37 (18–75) 32 (22–66) 41.5 (18–75) <0.01†
Core/volume, cores/mL 1.05 (0.80–1.77) 1.05 (0.80–1.31) 1.05 (0.80–1.77) 0.07†
†Mann-Whitney U test, ‡Chi-squared test
TRUS transrectal ultrasound, PSA prostate specific antigen, DRE digital rectal examination, HGPIN high grade prostatic intraepithelial neoplasia, ASAP atypical small
acinar proliferation, TTSB transperineal template-guided sasturation biopsy, Core/volume number of cores per unit volume of prostate
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another after 10 days. Prostate volumes of the two patients
were 73.1 and 46.0 mL. One patient had habitually used
an alpha-1 adrenogenic receptor antagonist for benign
prostatic hyperplasia.
Discussion
The overall cancer detection rate of the present study was
51.5%; this was comparable to that reported in the previ-
ous studies (26–68%) [8–10, 15, 18, 22, 24–29]. Studies in-
cluding more than 100 cases have reported detection rates
of 35.6–54.8% [9, 10, 18, 22, 28, 29]. Although the tech-
nique of TTSB and the number of biopsy cores varied
among these studies, the cancer detection rate in repeated
biopsy patients was almost similar.
Significant cancer by saturation biopsy was defined by
Epstein et al. as follows: (a) Gleason score less than 7
and the number of positive cores as three or fewer or (b)
Gleason score less than 7 and the maximal millimeters
of cancer in one core less than 4.5 mm, with the total
millimeters of cancer for all cores not exceeding 5.5 mm
[23]. Previous studies have found that incidence rates of
clinically significant cancer were 85.1 and 86.7% based
on the Epstein’s criteria [9, 24]. The present result
(79.8%) was lower than those of these previous studies.
Although increasing the number of cores may contribute
to the high detection rate of insignificant cancer, the rate
of detection of significant cancer in the present study
was still high. Based on these results, TTSB should be
considered for patients with persistent clinical suspicion
of PCa without a negative previous biopsy.
In the present study, prostate volume showed a strong
correlation with number of biopsy cores, and the mean
number of biopsy cores per unit prostate volume was
1.06. This number is the highest in reports about TTSB
[8–10, 13, 15, 18, 24–27]. However, the rate of detection
of PCa was almost the same as that in other reports. This
finding indicates that it is not necessary to sample as many
cores as in our methods for detecting PCa. Subsequently,
Table 2 The number of positive cores and cancer grade
Count
n (%) n = 53










Table 3 Univariate and multivariate analysis of factors that
predict positive for prostate cancer
Variables Univariate analysis Multivariate analysis
Categories Odds ratio (95% CI) P Odds ratio (95% CI) P
Age
≤ 70.3 (Ref) (Ref)
> 70.3 3.80 (1.68–8.61) <0.01 4.96 (1.67–14.7) <0.01
No. of TURSBs
≤ 1 (Ref)
> 1 0.70 (0.31–1.60) 0.78
No. cores obtained by pre-TURSBs
≤ 10 (Ref)
> 10 1.01 (0.87–1.16) 0.91
PSA
≤ 9.3 (Ref)
> 9.3 1.85 (0.83–4.07) 0.12
Free PSA ratio
≤ 13.6 (Ref) (Ref)
> 13.6 0.33 (0.14–0.78) 0.01 0.45 (0.13–1.60) 0.22
PSA density
≤ 0.27 (Ref) (Ref)
> 0.27 2.69 (1.20–6.01) 0.02 2.03 (0.468–6.01) 0.20
PSA velocity
≤ 1.2 (Ref)
> 1.2 1.91 (0.86–4.25) 0.11
DRE
Benign (Ref) (Ref)
Suspicious 3.73 (1.12–12.3) 0.03 2.87 (0.72–11.5) 0.13
TRUS
Benign (Ref)
Suspicious 2.20 (0.81–6.03) 0.12
Prostate volume
≤ 34.1 (Ref) (Ref)
> 34.1 0.24 (0.11–0.55) <0.01 0.28 (0.09–0.90) 0.03
HGPIN on previous biopsy
Absent (Ref)
Present 1.11 (0.35–3.58) 0.85
ASAP on previous biopsy
Absent (Ref)
Present 4.23 (0.86–21.2) 0.08
Core/volume
≤ 1.05 (Ref)
> 1.05 3.28 (0.41–24.5) 0.26
TRUSB transrectal ultrasound -guided biopsy, PSA prostate specific antigen,
DRE digital rectal examination, TRUS transrectal ultrasound, HGPIN high grade
prostatic intraepithelial neoplasia, ASAP atypical small acinar proliferation, TTSB
transperineal template-guided sasturation biopsy
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the number of cores may be reduced than that in our
method. However, the optimal number of cores for satur-
ation biopsy should be evaluated in the future.
Prostate volume has been considered a negative pre-
dictor of positive PCa by transperineal prostate biopsy in
other reports [10, 28]. Merrick et al. used a 24-region
technique with a median (mean, range) of 50.0 (51.1,
24–66) biopsy cores for patients whose mean prostate
volume was 78.6 ml [10]. Symons et al. used a 14-region
technique with a median (mean, range) of 15 (19.2, 4–
47) biopsy cores for patients whose mean prostate vol-
ume was 45.8 ml [28]. In the present study, larger pros-
tate volume predicted negative for PCa [odds ratio (OR),
0.29; 95%CI, 0.09–0.90] with a median (mean, range) of
37 (40.2, 18–75) biopsy cores for patients whose mean
prostate volume was 38.5 ml. Even with this high num-
ber of biopsy cores per volume, large prostate volume
was a negative predictor. This finding means that pa-
tients who have large prostates do not tend to have PCa.
Based on these results and the detection rate with the
high number of cores per volume in the present study,
we can omit repeat biopsy for patients requiring re-
peated biopsy with large prostate. However, the positive
predictive factors in the population of patients with large
prostate should be determined in the future.
Multivariate analysis showed that age was a predictor
of positive PCa. The median age of the patients (70 years)
was higher than that in other reports [8–10]. It is be-
lieved [29] that the detection rate of PCa is higher in
elderly than in younger men.
The reported incidence of AUR from TTSB ranged
from 10 to 39% [10, 16–19] and obtaining more biopsy
cores appears to have led to a high risk of AUR. In a pre-
vious study, Buskirk et al. [15] showed the relationship
between needle trauma and AUR after TTSB. To pre-
vent AUR, Ekwueme et al. [9] showed the safety of
TTSB at 10-mm intervals by avoiding the periurethral
region and reported the incidence of AUR as 5.9%. We
obtained a low AUR rate of 1.9% by performing TTSB as
described by Ekwueme et al., although we obtained more
biopsy cores. Possible reasons for low rate of AUR are as
follows: (a), catheterization overnight for all patients (b),
smaller prostate volume in the patient population than
other reports of saturation biopsy, and (c) avoiding in-
sertion of needle to the periurethral region. In other
studies, all patients were not catheterized overnight. [10,
11, 17–19] Prostate volume is a predictive factor for
AUR [9]. AUR rate may rise in patient groups that in-
clude patients with larger prostates. However, in the
present study, the mean prostate volume was smaller
than that in other reports.
The present study had several limitations. First, it was
retrospective study. Second, the median prostate volume
in this study was smaller than that in other reports from
Western countries. Indeed, the prostate volume of Japa-
nese patients is smaller than that in Western populations
[30]. Third, a control group of standard re-biopsy was
lacking. The final limitation was the small cohort size.
Conclusions
We demonstrated the feasibility of TTSB aimed at sam-
pling one core for each milliliter of prostate volume for
patients with persistent clinical suspicion of PCa who
had undergone at least one negative TRUS biopsy. A
relatively high cancer detection rate (51.5%) and signifi-
cant cancer detection rate (79.8%) could be achieved
with a low AUR rate (1.9%).
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